Moberg Pharma and Karo Healthcare have signed an exclusive agreement for the launch of MOB-015/Terclara in Europe, tapping into 19 markets.

Karo Healthcare has appointed Philip Hampden-Smith as COO, bringing two decades of international operations experience from Reckitt to enhance the company's growth strategy.

Perrigo Company plc has finalized the sale of its Dermacosmetics brand to Karo Healthcare, receiving €306 million to reduce debt. This decision aligns with Perrigo's strategic focus.

Karo Healthcare has appointed Karine Martin as CFO, bringing over 20 years of financial expertise to strengthen its financial foundation.

Moberg Pharma has secured an exclusive license with Karo Healthcare to commercialize MOB-015, Terclara in 19 major European markets. This collaboration enhances growth opportunities on a large scale.

Karo Healthcare has secured an exclusive licensing agreement with Moberg Pharma for the commercialization of MOB-015 across 19 European countries, enhancing its market presence with a new antifungal treatment.

Karo Healthcare has appointed Konstanze Gallinatus as its Chief Transformation Officer, aiming to accelerate growth and integration strategies across the company.

Karo Healthcare has confirmed the acquisition of numerous skin health brands, further strengthening its market presence in Northern Europe and enhancing its commitment to consumer health.

EQT has agreed to sell Karo Healthcare to KKR, marking a significant milestone in the evolution of this leading European consumer health platform.

EQT has officially sold Karo Healthcare to KKR, marking a transformative chapter for the pan-European consumer health platform. With a focus on growth, Karo aims to leverage KKR's investment expertise for further expansion.